ライフサイエンスコーパス: obstructive sleep apnoea

1 which are rarely developed specifically for obstructive sleep apnoea.

2 incident T2DM, hypertension, angina, MI, and obstructive sleep apnoea.

3 na, Spain, for abnormal sleep behaviours and obstructive sleep apnoea.

4 the metabolic syndrome, type 2 diabetes, and obstructive sleep apnoea.

5 ics for upper airway motor disorders such as obstructive sleep apnoea.

6 d in sudden infant death syndrome (SIDS) and obstructive sleep apnoea.

7 reflex function is impaired in patients with obstructive sleep apnoea.

8 e to promoting hypertension in patients with obstructive sleep apnoea.

9 ly to the major clinical problem of cyclical obstructive sleep apnoea.

10 provide a mechanism linking hypertension to obstructive sleep apnoea.

11 k of cardiovascular disease in patients with obstructive sleep apnoea.

12 re (NCPAP) is widely used as a treatment for obstructive sleep apnoea.

13 0.40-0.87);MI, 0.28 (95% CI 0.10-0.74); and obstructive sleep apnoea, 0.55 (95% CI 0.40-0.87).

14 Obstructive sleep apnoea, a syndrome that leads to recur

15 The assessment of how obstructive sleep apnoea affects cognition depends on th

16 hronic hypoxia as a consequence of increased obstructive sleep apnoea and cardiovascular disease.

17 active at rest, e.g. essential hypertension, obstructive sleep apnoea and heart failure.

18 of hypertension, but the association between obstructive sleep apnoea and myocardial infarction, stro

19 review, we focus on the association between obstructive sleep apnoea and stroke reviewing both the e

20 herent complexity of the association between obstructive sleep apnoea and the brain.

21 Obstructive sleep apnoea and type 2 diabetes are common

22 ocardial infarction (MI), stroke, fractures, obstructive sleep apnoea, and cancer; mortality; and res

23 n have atypical phenotypes including ptosis, obstructive sleep apnoea, and the occurrence of seizures

24 ating many sleep-related disorders including obstructive sleep apnoea (apnea), REM sleep behaviour di

25 abnormal sleep movements and behaviours and obstructive sleep apnoea, as confirmed by polysomnograph

26 Obstructive sleep apnoea can be diagnosed on the basis o

27 Obstructive sleep apnoea causes sleepiness, road traffic

28 tive parallel trial of therapeutic NCPAP for obstructive sleep apnoea compared with a control group o

29 s that can cause brain hypoperfusion such as obstructive sleep apnoea, congestive heart failure, card

30 nt for metabolic abnormalities in those with obstructive sleep apnoea could reduce cardiovascular dis

31 As will be discussed, management of obstructive sleep apnoea could soon transition from a so

32 Men with obstructive sleep apnoea, defined as an Epworth sleepine

33 Dips suggestive of obstructive sleep apnoea did not predict CNS events, and

34 are change in blood pressure in 118 men with obstructive sleep apnoea (Epworth score > 9, and a > 4%

35 Patients with obstructive sleep apnoea experience chronic intermittent

36 ardiovascular related pathologies, including obstructive sleep apnoea, heart failure and diabetes.

37 Obstructive sleep apnoea/hypopnoea syndrome, depression

38 ioglossal activity observed in patients with obstructive sleep apnoea (i.e. reflex compensation for a

39 Early identification of obstructive sleep apnoea in patients with metabolic dysf

40 Obstructive sleep apnoea is a common disease that is now

41 Obstructive sleep apnoea is a disease of increasing impo

42 Obstructive sleep apnoea is an increasingly common disor

43 Obstructive sleep apnoea is associated with raised blood

44 e shown that primary sleep disorders such as obstructive sleep apnoea may worsen epilepsy and treatme

45 re dips per h of more than 4% SaO2 caused by obstructive sleep apnoea on overnight sleep study, were

46 Obstructive sleep apnoea (OSA) and type 2 diabetes frequ

47 ed a small group of elderly individuals with obstructive sleep apnoea (OSA) for comparison (n = 3, ag

48 etermine whether PA and vLTF are enhanced in obstructive sleep apnoea (OSA) participants compared to

49 irway pressure (CPAP) for moderate to severe obstructive sleep apnoea (OSA) syndrome have been establ

50 mulating blood O2 saturation profiles during obstructive sleep apnoea (OSA), have been shown to exhib

51 mulating blood O2 saturation profiles during obstructive sleep apnoea (OSA), have been shown to exhib

52 eep fragmentation (SF), a primary feature of obstructive sleep apnoea (OSA), impairs hippocampal long

53 Obstructive sleep apnoea (OSA), which is characterized b

54 wn to reduce loop gain (LG) in patients with obstructive sleep apnoea (OSA), yet its effects on the o

55 ociated with a relatively high prevalence of obstructive sleep apnoea (OSA).

56 ociated with a relatively high prevalence of obstructive sleep apnoea (OSA).

57 reathing on return to sleep in patients with obstructive sleep apnoea (OSA).

58 ce to suggest that acetazolamide may improve obstructive sleep apnoea (OSA).However, how acetazolamid

59 airway pressure, the treatment of choice for obstructive sleep apnoea, reduces sleepiness and improve

60 ts, video polysomnography showed features of obstructive sleep apnoea, stridor, and abnormal sleep ar

61 cles are important in the pathophysiology of obstructive sleep apnoea syndrome (OSA).

62 clearly important in the pathophysiology of obstructive sleep apnoea syndrome (OSA).

63 The contribution of genetic factors to obstructive sleep apnoea syndrome (OSAS) has led to a be

64 etabolism, nonalcoholic fatty liver disease, obstructive sleep apnoea syndrome, erectile dysfunction,

65 are clearly important in the pathogenesis of obstructive sleep apnoea syndrome.

66 done in the past two decades indicates that obstructive sleep apnoea, through the effects of intermi

67 nic rhinosinusitis, gastroesophageal reflux, obstructive sleep apnoea, vocal cord dysfunction, obesit

68 relates to the pathogenesis and treatment of obstructive sleep apnoea, we have developed a novel appl

69 the most recent insights and discoveries in obstructive sleep apnoea, with a focus on diagnostics an